title: Case Report Diffuse large B-cell lymphoma in the primary bone marrow.
abstract: This study aimed to improve understanding of the diagnosis, treatment, and prognosis of primary bone marrow (PBM) diffuse large B-cell lymphoma (DLBCL), a rare illness. We report a 56-year-old man with pancytopenia and hyperbilirubinemia but without lymphadenopathy, hepatomegaly, or splenomegaly. Bone marrow aspiration, flow cytometry, biopsy, and immunohistochemistry confirmed DLBCL. Two cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone were administered. Blood cell numbers and hyperbilirubinemia improved. Although the patient did not completely recover, he survived for at least 3 years after chemotherapy and receiving blood transfusions. PBM DLBCL is a distinct, aggressive lymphoma characterized by lymphoma cells only in the bone marrow and effectively treated via chemotherapy. Prognoses for PBM DLBCL vary.
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China yinghucn@163.com.
authors.forename: Y
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.
authors.forename: S L
authors.initials: SL
authors.lastname: Chen
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.
authors.forename: Z X
authors.initials: ZX
authors.lastname: Huang
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.
authors.forename: W
authors.initials: W
authors.lastname: Gao
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.
authors.forename: N
authors.initials: N
authors.lastname: An
mesh_terms: D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010198:Pancytopenia / Q000097:blood* / Q000150:complications / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone